0.58%
-20.80%
-27.64%
-23.77%
11.01%
114.37%
88.52%
AI Spotlight on CRNX
Company Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases.
Crinetics Pharmaceuticals, Inc.was incorporated in 2008 and is headquartered in San Diego, California.
Market Data
| Last Price | 40.49 |
| Change Percentage | 0.58% |
| Open | 40.35 |
| Previous Close | 40.26 |
| Market Cap ( Millions) | 3755 |
| Volume | 238394 |
| Year High | 62.53 |
| Year Low | 35.51 |
| M A 50 | 50.5 |
| M A 200 | 50.6 |
Financial Ratios
| FCF Yield | -5.42% |
| Dividend Yield | 0.00% |
| ROE | -36.12% |
| Debt / Equity | 6.31% |
| Net Debt / EBIDTA | 86.94% |
| Price To Book | 3.89 |
| Price Earnings Ratio | -11.67 |
| Price To FCF | -18.45 |
| Price To sales | 3614.45 |
| EV / EBITDA | -11.46 |
News
- Jan -10 - Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jan -10 - Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
- Jan -06 - Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
- Jan -02 - Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
- Dec -11 - Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dec -09 - Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
- Nov -13 - Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Transcript
- Nov -12 - Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
- Nov -12 - Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
- Nov -11 - Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Oct -10 - Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Oct -09 - Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
- Oct -07 - Did this congressman benefit from a stock buy just before FDA approval?
- Sep -26 - Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
- Sep -10 - Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aug -29 - Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
- Aug -12 - Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aug -09 - Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2024 Earnings Call Transcript
- Aug -08 - Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
- Aug -08 - Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Therapeutics
Expected Growth : 10.43 %
What the company do ?
Crinetics Pharmaceuticals' Novel Therapeutics is a pipeline of non-peptide, oral somatostatin receptor agonists for treating neuroendocrine tumors and other diseases.
Why we expect these perspectives ?
Crinetics Pharmaceuticals' Novel Therapeutics segment growth is driven by increasing adoption of its pipeline of novel, oral somatostatin agonists for rare endocrine disorders, strong clinical trial results, and strategic partnerships. The company's focus on rare diseases with high unmet needs, combined with its innovative approach, positions it for continued growth.
Crinetics Pharmaceuticals, Inc. Products
| Product Range | What is it ? |
|---|---|
| Parsaclisib | An oral, selective inhibitor of the MALT1 protease, being developed for the treatment of hematologic malignancies, including mantle cell lymphoma and diffuse large B-cell lymphoma. |
| CRN0477 | An oral, non-peptide somatostatin receptor subtype 5 (SST5) agonist, being developed for the treatment of congenital hyperinsulinism and endocrine disorders. |
| CRN0481 | An oral, non-peptide ACTH antagonist, being developed for the treatment of Cushing's disease and other disorders related to excess ACTH production. |
| CRN0491 | An oral, non-peptide melanocortin receptor 1 (MC1R) agonist, being developed for the treatment of inflammatory disorders, including vitiligo. |
Crinetics Pharmaceuticals, Inc.'s Porter Forces
Threat Of Substitutes
Crinetics Pharmaceuticals, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for the diseases it targets.
Bargaining Power Of Customers
Crinetics Pharmaceuticals, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternatives.
Bargaining Power Of Suppliers
Crinetics Pharmaceuticals, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and services.
Threat Of New Entrants
Crinetics Pharmaceuticals, Inc. has a high threat of new entrants due to the growing interest in biotechnology and pharmaceuticals, making it easier for new companies to enter the market.
Intensity Of Rivalry
Crinetics Pharmaceuticals, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 8.76% |
| Debt Cost | 3.95% |
| Equity Weight | 91.24% |
| Equity Cost | 7.12% |
| WACC | 6.84% |
| Leverage | 9.60% |
Crinetics Pharmaceuticals, Inc. : Quality Control
Crinetics Pharmaceuticals, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| SRPT | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It … |
| CYTK | Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily … |
| RNA | Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The … |
| AGIO | Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) … |
| SWTX | SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Agios Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
Avidity Biosciences
A-Score
1-Year Total Return ->
🥉
Crinetics Pharmaceuticals
A-Score
1-Year Total Return ->
4
Sarepta Therapeutics
A-Score
1-Year Total Return ->
5
Cytokinetics
A-Score
1-Year Total Return ->
6
